Phaseline

Targets › MUC16

MUC16 (Mucin-16): drug programs, companies and trials

5 programs from 5 companies in 10 trials: 7 Phase 1, 2 Phase 2, 1 Phase 3; Oncology; next expected readout Dec 2026.

Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. (UniProt, Q8WXI7)

Open in Phaseline: the race on MUC16, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
CanariaBioOregovomab
Mucin-16 other
MUC16Phase 3Carcinoma, Ovarian Epithelial; Recurrent Ovarian Cancer; Ovarian Neoplasm Epithelial; Ovarian Cancer by FIGO StageDec 2026
Beijing BiotechEB-NK-MF CAR-NK cells
Dual-targeting CAR-NK cells engineered to target Mesothelin and Folate Receptor alpha (wit
MSLN, FOLR1, MUC16, TROP2Phase 1Advanced Solid Tumors; Epithelial Ovarian CancerFeb 2027
Memorial Sloan Kettering Cancer Center4H11-28z/fIL-12/EGFRt+ genetically-modified T cells
CAR-T cells engineered to target MUC16ecto antigen and secrete IL-12
MUC16Phase 1Solid TumorsAug 2027
Whitehawk TherapeuticsHWK-016
MUCIN-16-targeted antibody-drug conjugate
MUC16Phase 1PROCFeb 2028
Regeneron Pharmaceuticals27T51
MUC16-targeting CAR T cell therapy
MUC16Phase 1Epithelial Ovarian CancerMay 2030

Conditions

Epithelial Ovarian Cancer (3) Carcinoma, Ovarian Epithelial (1) Recurrent Ovarian Cancer (1) Ovarian Neoplasm Epithelial (1) Ovarian Cancer by FIGO Stage (1) Advanced Solid Tumors (1) Solid Tumors (1) PROC (1)

Modalities

mixed (4), antibody (1)

Companies

CanariaBio (1) Beijing Biotech (1) Memorial Sloan Kettering Cancer Center (1) Regeneron Pharmaceuticals (1) Whitehawk Therapeutics (1)

Related targets

MSLN (1) FOLR1 (1) TROP2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.